JUNO THERAPEUTICS INC's ticker is JUNO and the CUSIP is 48205A109. A total of 153 filers reported holding JUNO THERAPEUTICS INC in Q2 2015. The put-call ratio across all filers is 2.17 and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2016 | $40,470,000 | -33.6% | 2,146,963 | +5.7% | 0.01% | -46.2% |
| Q3 2016 | $60,972,000 | -19.3% | 2,031,736 | +3.4% | 0.01% | -23.5% |
| Q2 2016 | $75,512,000 | +30.6% | 1,964,403 | +29.5% | 0.02% | +30.8% |
| Q1 2016 | $57,799,000 | -1.1% | 1,517,425 | +14.1% | 0.01% | 0.0% |
| Q4 2015 | $58,462,000 | +879.1% | 1,329,599 | +806.0% | 0.01% | +550.0% |
| Q3 2015 | $5,971,000 | +21.8% | 146,747 | +59.7% | 0.00% | +100.0% |
| Q2 2015 | $4,901,000 | +5.1% | 91,904 | +19.5% | 0.00% | 0.0% |
| Q1 2015 | $4,665,000 | – | 76,903 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Biomark Capital Management Co. LLC | 2,168,601 | $65,080,000 | 86.12% |
| Crestline Management, LP | 17,348,799 | $520,637,000 | 66.02% |
| Omega Fund Management, LLC | 1,229,512 | $36,898,000 | 28.17% |
| SIB LLC | 100,000 | $3,001,000 | 2.42% |
| Clarius Group, LLC | 117,896 | $3,538,000 | 1.65% |
| BB BIOTECH AG | 1,405,000 | $42,164,000 | 1.48% |
| Duquesne Family Office | 493,000 | $14,795,000 | 1.31% |
| First Washington CORP | 65,320 | $1,960,000 | 1.10% |
| PFM Health Sciences, LP | 1,124,285 | $33,740,000 | 0.99% |
| Partner Investment Management, L.P. | 18,376 | $551,000 | 0.82% |